Immune Monitoring in Sensitized Patients at Risk of Rejection
NCT03794817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112
Last updated 2019-01-07
Summary
The purpose of this study is to test the effect of anti-rejection medications on your immune system
Conditions
Sponsors & Collaborators
-
University of California, San Francisco
lead OTHER
Principal Investigators
-
Flavio Vincenti, M.D. · University of California, San Francisco
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-08-20
- Primary Completion
- 2017-09-08
- Completion
- 2017-09-08
Countries
- United States
Study Locations
More Related Trials
-
Renal Transplantation With Immune Monitoring
NCT00419575 ·Status: COMPLETED
-
Protective Immunity Project 01
NCT00788021 ·Status: COMPLETED
-
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
NCT03897205 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant
NCT02208791 ·Status: UNKNOWN ·Phase: PHASE4
-
Felzartamab in Late Antibody-Mediated Rejection
NCT05021484 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates
NCT03507348 ·Status: TERMINATED ·Phase: NA
-
Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
NCT00261547 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant
NCT00167791 ·Status: WITHDRAWN ·Phase: NA
-
Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection
NCT03991780 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
NCT00307125 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-HLA Immunization And Immunosuppressive Therapy Management In Kidney Transplant Patients Returning to Dialysis
NCT05282875 ·Status: UNKNOWN
-
Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study
NCT00895206 ·Status: COMPLETED ·Phase: PHASE4
-
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
NCT04935177 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients
NCT02267512 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
NCT00446251 ·Status: COMPLETED ·Phase: PHASE2
-
Microbiome and Immunosuppression: The Mission Study
NCT04953715 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
NCT04835948 ·Status: COMPLETED
-
Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients
NCT02560857 ·Status: COMPLETED
-
Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART)
NCT06802822 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
NCT03994783 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
NCT06685757 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of Rituximab in Renal Transplantation
NCT00255593 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab for Prevention of Rejection After Renal Transplantation
NCT00565331 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Randomized Trial for Mixed Acute Rejection
NCT00771875 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Monitoring to Facilitate Belatacept Monotherapy
NCT04177095 ·Status: COMPLETED ·Phase: PHASE4